HJB647 high dose
Phase 1
NovartisHJB647 high dose is one of 4 therapeutic programs targeting Heart Failure With Reduced Ejection Fraction. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
8 competitors in Heart Failure With Reduced Ejection Fraction
#DrugCompanyPhaseTrials
1Lumacaftor
Vertex PharmaceuticalsPhase 2
Ozempic
Novo NordiskPreclinical
HJB647 Low Dose
NovartisPhase 1
HJB647 high dose
NovartisPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Heart Failure With Reduced Ejection Fraction1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for HJB647 high dose. EMBL-EBI & Wellcome Sanger Institute.
- [3]